--- title: "Apogee Therapeutic | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285932264.md" datetime: "2026-05-11T11:22:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285932264.md) - [en](https://longbridge.com/en/news/285932264.md) - [zh-HK](https://longbridge.com/zh-HK/news/285932264.md) --- # Apogee Therapeutic | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -1.06, beating the estimate of USD -1.0823. EBIT: As of FY2026 Q1, the actual value is USD -91.51 M. ### Financial and Operational Metrics #### Net Loss Apogee Therapeutics, Inc. reported a net loss of - $74,111 thousand for the three months ended March 31, 2026, compared to - $55,339 thousand for the same period in 2025, representing an increase of - $18,772 thousand in net loss. #### Operating Expenses Total operating expenses increased to $82,772 thousand for the three months ended March 31, 2026, from $63,096 thousand for the three months ended March 31, 2025, an increase of $19,676 thousand. Loss from operations was - $82,772 thousand in 2026, compared to - $63,096 thousand in 2025. - **Research and Development (R&D) Expense:** R&D expenses increased by $14.4 million to $60,819 thousand for the three months ended March 31, 2026, from $46,387 thousand in the prior year period. This increase was primarily driven by: - Zumilokibart (APG777) program costs increasing by $5.0 million to $19,542 thousand in 2026 from $14,571 thousand in 2025, due to increased clinical trial-related expenses for the APEX Phase 2 clinical trial. - APG990/APG279 program costs increasing by $2.2 million to $5,444 thousand in 2026 from $3,213 thousand in 2025, due to increased clinical manufacturing activities and clinical trial expenses. - External-discovery related costs and other expenses (including APG808) increased by $3.0 million to $8,433 thousand in 2026 from $5,437 thousand in 2025, mainly due to higher professional service fees. - Personnel-related R&D expenses (excluding equity-based compensation) increased by $3.2 million to $18,542 thousand in 2026 from $15,296 thousand in 2025. - Equity-based compensation for R&D increased by $3.2 million to $8,527 thousand in 2026 from $5,372 thousand in 2025. - APG333/APG273 program costs decreased by $2.2 million to $254 thousand in 2026 from $2,434 thousand in 2025, due to reduced clinical manufacturing activities and preclinical/clinical trial expenses. - **General and Administrative (G&A) Expense:** G&A expenses rose by $5.3 million to $21,953 thousand for the three months ended March 31, 2026, from $16,709 thousand in the prior year period. This increase was primarily due to increases in equity-based compensation and personnel-related expenses of $2.9 million and $2.3 million, respectively, driven by increased headcount and higher fair value of equity awards granted. #### Other Income and Taxes Net interest income increased by $0.9 million to $8,740 thousand in 2026, compared to $7,840 thousand in 2025, primarily from interest on cash, cash equivalents, and marketable securities. The provision for income taxes was - $79 thousand in 2026, compared to - $83 thousand in 2025. #### Cash Flows - **Net Cash used in Operating Activities:** Net cash used in operating activities was - $55,570 thousand for the three months ended March 31, 2026, compared to - $48,477 thousand for the same period in 2025. This was primarily due to a net loss of - $74,111 thousand and amortization of discounts on marketable securities of - $1,549 thousand, partially offset by non-cash charges for equity-based compensation of $17,155 thousand, lease expense of $980 thousand, and net changes in operating assets and liabilities of $1,500 thousand in 2026. - **Net Cash (used in) provided by Investing Activities:** Net cash used in investing activities was - $35,349 thousand for the three months ended March 31, 2026, primarily from $183,244 thousand in marketable securities purchases, partially offset by $147,895 thousand in maturities of marketable securities. In 2025, net cash provided by investing activities was $12,982 thousand, primarily from $115,500 thousand in maturities of marketable securities, partially offset by $98,201 thousand in marketable securities purchases and $4,317 thousand in property and equipment purchases. - **Net Cash provided by Financing Activities:** Net cash provided by financing activities was $411,167 thousand for the three months ended March 31, 2026, mainly from the issuance and sale of common stock. In 2025, financing activities provided $622 thousand, primarily from the exercise of stock options. #### Liquidity and Capital Resources As of March 31, 2026, Apogee Therapeutics, Inc. held $451.8 million in cash and cash equivalents, $608.1 million in marketable securities, and $198.4 million in long-term marketable securities. The company had an accumulated deficit of - $635.9 million as of March 31, 2026. Apogee Therapeutics, Inc.’s existing cash, cash equivalents, marketable securities, and long-term marketable securities are estimated to be sufficient to fund operating expenses and capital requirements through at least the next 12 months from the issuance date of the financial statements and into 2029 through a planned Biologics License Application (BLA) filing for zumilokibart in atopic dermatitis (AD). #### Strategic Outlook and Program Updates Apogee Therapeutics, Inc. continues to advance its pipeline, including zumilokibart (APG777), APG279, APG273, and APG808. The company expects to report 16-week topline induction data for zumilokibart in AD in Q2 2026 and plans to initiate Phase 3 trials in AD in H2 2026, targeting a potential launch in 2029. Additionally, Apogee Therapeutics, Inc. plans to announce further clinical plans for APG273 in 2026 and share plans for the Phase 2 ASPIRE trial for asthma and the Phase 2 ELEVATE trial for eosinophilic esophagitis (EoE) in H2 2026. ### Related Stocks - [APGE.US](https://longbridge.com/en/quote/APGE.US.md) ## Related News & Research - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)